Most people still think of Anthropic as the company behind Claude, a very good chatbot that competes with ChatGPT. That framing is starting to look outdated.

In the span of a single week, Anthropic made two moves that, taken together, paint a very different picture: the company is quietly building toward something far larger than a chat interface.

The Chip Play

According to TechCrunch, Anthropic is in discussions with Samsung to develop a custom AI chip. The talks are still early — Anthropic reportedly hasn’t settled on what the chip will do, how it will fit into server infrastructure, or how powerful it needs to be — but the conversation is happening, and that alone is significant.

For context, chips are the single biggest bottleneck in AI right now. Nvidia dominates the market, and demand for its hardware has far outpaced supply. Building a custom chip gives an AI company more control over its compute costs, its capabilities, and its independence from any single supplier.

Anthropicis not alone in chasing this. According to TechCrunch, OpenAI recently teamed up with Broadcom to build its own inference chip, called “Jalapeño,” which OpenAI claims delivers better performance per watt than competing chips. Amazon and Google both offer custom chips through their cloud platforms. Anthropic, by contrast, currently relies on a mix of chips from Google, Amazon, and Nvidia — a diversified approach the company told TechCrunch it plans to maintain even as it explores new options.

Samsung is a logical partner here. The company already works closely with Nvidia, producing chips needed to train and run AI models, and has also held chip-making discussions with Google. It knows the space.

The Drug Development Bet

The chip news would be enough on its own. But just a day later, The Verge reported on another announcement: Anthropic wants to develop its own drugs.

At an event called “The Briefing: AI for Science,” Anthropic unveiled Claude Science, described as an “AI workbench for scientists” that brings together fragmented tools and datasets into a single environment and can generate figures and visuals. The company already counts a long list of biotech and pharma companies among its customers.

But it didn’t stop there. Eric Kauderer-Abrams, Anthropic’s head of life sciences, said the company intends to discover treatments for “neglected” diseases — conditions that tend to get underfunded because they primarily affect poorer populations and don’t offer the commercial returns that drive Big Pharma investment.

As The Verge noted, this is one of the most direct public commitments by a major frontier AI lab to actually develop drugs itself, not just sell tools to drugmakers. It puts Anthropic in the unusual position of being both a software vendor to pharmaceutical companies and a potential competitor to them.

The details remain thin. Anthropic hasn’t said which diseases it will target first, whether it will partner with other companies for lab work or clinical trials, or what it would do if it actually finds a promising drug candidate. Experts interviewed by The Verge pointed out that “AI drug discovery” is a broad term covering everything from molecule generation to data analysis — and that essentially every major drug company is already using AI in some form.

Why This Week Matters

Neither announcement is a finished product. The Samsung chip talks could stall. The drug ambitions could remain vague for years. Anthropic itself was measured in its public comments on both.

But that’s almost the point. What’s visible here isn’t a product launch — it’s a strategic posture. Anthropic is moving to control more of its own hardware stack while simultaneously reaching into one of the most complex and high-stakes domains that AI could touch: human medicine.

This is a company that, at least publicly, has always emphasized safety and long-term thinking over speed. The moves this week suggest that long-term thinking now includes becoming infrastructure — not just for conversations, but for the chips that power AI and the science that AI might one day transform.

The chatbot era of Anthropic may still be its present. But the company seems to be building for a very different future.